JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Foshan First People's Hospital, Foshan, Guangdong, China
Contact: Study coordinator (Yichu Nie, Doctor) · Nieyichu2@126.com · +086 0757-83162054

Study leads

Ke Huang, Doctor
Study Chair
Shenzhen Genocury Biotech Co., Ltd.

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Parkville, Australia

Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Iowa City, United States

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma (RRMM)

Abroad (travel likely)RecruitingPHASE1

Boston, United States · Boston, United States

Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma(MM)

Abroad (travel likely)RecruitingPHASE1

Xi’an, China